Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy by O'Cathail, SM et al.
Radiotherapy and Oncology 151 (2020) 280–286Contents lists available at ScienceDirect
Radiotherapy and Oncology
journal homepage: www.thegreenjournal .comOriginal ArticleSuperior outcomes of nodal metastases compared to visceral sites in
oligometastatic colorectal cancer treated with stereotactic ablative
radiotherapyhttps://doi.org/10.1016/j.radonc.2020.08.012
0167-8140/ 2020 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author at: Wolfson Wohl Cancer Research Centre, Institute of
Cancer Sciences, Garscube Campus, Switchback Road, Glasgow G61 1BD, UK.
E-mail address: Sean.OCathail@glasgow.ac.uk (S.M. O’Cathail).Sean M. O’Cathail a,⇑, Thomas Smith b, Rob Owens c, Anthi Zeniou d, Yatman Tsang b, Daniel L.P. Holyoake e,
Louise Murray d, Mark Harrison b, Maria A. Hawkins f
a Institute of Cancer Sciences, University of Glasgow; bMount Vernon Cancer Centre; cOxford University NHS Foundation Trust; d Leeds Cancer Centre; eNorwich and Norfolk University
NHS Foundation Trust; and fMedical Physics and Biomedical Engineering, University College London and University College London Hospitals NHS Foundation Trust, UK
a r t i c l e i n f o a b s t r a c tArticle history:
Received 12 May 2020
Received in revised form 14 August 2020
Accepted 19 August 2020
Available online 29 August 2020
Keywords:
Colorectal
Stereotactic
SBRT
Oligometastatic
Lymph nodeBackground: Stereotactic ablative radiotherapy (SBRT) is a radical option for oligometastatic colorectal
cancer (CRC) patients, but most data relate to visceral metastases.
Methods: A prospective, multi-centre database of CRC patients treated with SBRT was interrogated.
Inclusion criteria were ECOG PS 0–2, 3 sites of disease, a disease free interval of >6 months unless syn-
chronous liver metastases. Primary endpoints were local control (LC), progression free survival (PFS) and
overall survival (OS).
Results: 163 patients (172 metastases) were analysed. The median FU was 16 months (IQR 12.2–22.85).
The LC at 1 year was 83.8% (CI 76.4%91.9%) with a PFS of 55% (CI 47%64.7%) respectively. LC at 1 year
was 90% (CI 83%99%) for nodal metastases (NM), 75% (63%90%) for visceral metastases (VM). NM had
improved median PFS (9 vs 19 months) [HR 0.6, CI 0.38–0.94, p = 0.032] and median OS (32 months vs not
reached) [HR 0.28, CI 0.18–0.7, p = 0.0062] than VM, regardless of whether the NM were located inside or
outside the pelvis. On multivariate analysis, NM and ECOG PS 0 were significant good prognostic factors.
An exploratory analysis suggests KRAS WT is also a good prognostic factor.
Conclusion: Nodal site is an important prognostic determinant of SBRT that should incorporated into
patient selection. We hypothesise this may have an immunoediting basis.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 151 (2020) 280–286 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Approximately 20% of colorectal cancer (CRC) patients present
with stage IV disease [1]. Of those that present at an early stage
and are treated radically, 20–30% will go on to develop metastatic
disease [2,3]. Systemic therapy is the main treatment for metas-
tases given the proven survival benefit, however metastasis direc-
ted therapy is increasingly being used to manage metastatic
deposits in an attempt to achieve long term benefit [4]. Aggressive
management of patients who have unresectable liver disease at the
time of diagnosis [5] using radiofrequency ablation (RFA) has
demonstrated an overall survival benefit versus standard of care
[6]. The recent randomised phase II SABR-COMET trial demon-
strated a survival benefit from the addition of stereotactic ablative
body radiotherapy (SBRT) in oligometastatic disease at extra-
cranial sites [7], where almost 20% of the patients had CRC. These
data suggest that CRC patients can derive significant benefit in lim-
ited metastatic disease.The oligometastatic state lies on a spectrum between localised
and disseminated disease [8]. A concrete definition is lacking with
the most common criteria being the number and location of radi-
ologically identifiable metastases. The ESMO consensus guidelines
for the management of patients with metastatic colorectal cancer,
defines oligometastases as five or sometimes more metastases at
two or three sites, primarily visceral and lymph nodes [9]. Data
from surgical cohorts in CRC demonstrate an improved 5-year OS
for patients with 1–3 resectable metastases, compared to 4–6, or
more than 6, respectively [10], suggesting burden of disease is
important. More recently there have been reports focusing on a
specific primary cancer type or a specific treated metastatic site
[11–15].
Visceral metastases (VM) are the most common metastases
from CRC that are treated with SBRT [16] and much of the litera-
ture to date has focussed on either liver or lung metastases [17].
In the SABR-COMET trial [7] most patients had visceral metastases,
while only 3 (6%) of metastases treated with SBRT were in lymph
nodes. There are little data available on the outcomes of lymph
node only oligometastases in colorectal cancer treated with SBRT.
S.M. O’Cathail et al. Radiotherapy and Oncology 151 (2020) 280–286The treatment options for these patients are limited to systemic
therapy, as RFA and surgery are less commonly performed, and
there is some debate about whether or not the entire nodal chain
should be treated. Furthermore, the mechanisms of spread for vis-
ceral and nodal oligometastases differ which may have implication
for outcomes.
We analysed a prospectively collected, multicentre cohort of
oligometastatic CRC patients treated with SBRT to identify differ-
ences in outcomes between treated visceral metastases (VM) and
lymph node metastases (NM) at oligometastatic sites.Methods
Study population
Patients with CRC were identified from a prospectively col-
lected register of patients [18] diagnosed with colorectal cancer
treated across three UK sites (Oxford, Mount Vernon, Leeds). Key
eligibility criteria were: confirmed histological diagnosis, ECOG
PS 0–2, 3 sites of disease and no more than 2 organ systems, no
brain metastases, primary tumour resected with a disease free
interval of >6 months (synchronous presentations were permitted
for liver metastases) as identified on multimodality imaging (CT,
PET and MRI as appropriate), adequate organ function and no sys-
temic treatment for 28 days or planned systemic treatment after
SBRT. All nodes were confirmed as isolated through review of serial
imaging. Patients with less than 3 months of follow were excluded.
All metastatic lesions were treated, where there was more than
one. All patients consented to collection of data as part of enrol-
ment in the SBRT treatment program which had received ethical
approval (North East – York Research Ethics Committee REC refer-
ence: 16_NE_0285).Table 1
Cohort characteristics.
Variable N = 163 %
Age 69 (Range 36–91)
Gender
Male 90 55
Female 73 45
ECOG
0 99 61
1 52 32
2 5 3
Unknown 7 4
Primary site
Rectum 81 50
Colon 82 50
Treated site
Liver 38 23
Lymph Node 86 53
Lung 34 21
Other* 5 3
Median BED 10 (across all sites) 79.2 Gy (IQR 48–105)
KRAS status
Wild type 45 28
Mutant 19 12
Not tested 99 61
GTV 9.725 cm3 (Range 2.03–39.2)Techniques of radiotherapy
All patients were scanned with helical CT using 5 mm interval.
Gross tumour volume (GTV) was outlined and clinical target vol-
ume (CTV) was equal to GTV for all lesions except liver metastases
where, a 5 mm margin in all directions was applied added to GTV
to define CTV. Radiotherapy planning CT images were co-
registered with diagnostic radiology at the treating oncologist’s
discretion. Where disease sites were subject to internal movement
(such as lung or liver), patients were planned using 4D-CT scan.
Abdominal compression or fiducial tracking [19] was used for
abdominal motion management. A margin of 3–5 mm, depending
on disease site and dimensions, was added to GTV/ CTV to obtain
the planning target volume (PTV). Details of radiation doses, which
varied according to tumour sites, are provided in Supplementary
Table 1. An a/b ratio of 10 was used for biologically effective dose
(BED) calculations. KRAS mutation status of the primary tumour
was collected by retrospective review of pathology reports. All
mutations were activating driver mutations and detected by next
generation sequencing of the primary tumour using a targeted
gene panel.Metachronous 135 83
Synchronous 28 17
Lines of chemotherapy
0 38 23
1 86 53
2 34 21
3 2 1
Number of metastasesǂ
1 151 93
2 10 6
3 2 1
*Tail of pancreas, left flank, pancreas bed, spine and penile bulb.
ǂ >1 metastases treated as a single GTV are considered as isolated metastases.Response assessment
First evaluation was planned 3 months after the end of the SBRT
and then every 3 months for the first year and every 6 months from
the second to the fifth year. Follow-up visits included clinical eval-
uation and diagnostic imaging (CT, MRI or PET scan) at treating
physician’s discretion. End points of the present study were local
control (LC), defined as absence of progression inside the SBRT
treated volume; locoregional progression (LRP), defined as pro-
gression outside the treated volume in an adjacent nodal station/281chain or within the same organ (liver/lung) and distant progression
(DP), as metastasis within another organ system or anatomically
remote from the treated lesion. Toxicity data was collected as part
of the overall treatment program and is publically available [20].Statistical analysis
All outcomes were calculated from date of SBRT treatment.
Time to any progression (LC/LRP/DP) was defined as PFS and over-
all survival (OS) treatment to either death or censoring. Univariate
analysis was performed with the log-rank test, and Cox propor-
tional hazards regression was used to estimate hazard ratios
(HR). The primary endpoints were PFS and OS. Multivariable step-
wise cox regression analysis was performed to evaluate the associ-
ation between clinical factors and survival, with a significance level
of p < 0.05. Survival analysis was performed using Cox regression
models and Kaplan Meier estimates with log rank testing. Median
follow-up was ascertained by reverse-censoring method. Patients
without the event of interest were censored at the time last known
to be event-free. All statistical analysis was performed using R sta-
tistical software [21].Results
A total of 184 patients were treated between September 2015
and October 2018. Nine were excluded as the treated site was
intracranial and 12 excluded due to inadequate or missing follow
up. The final cohort was 163 patients with 172 treated lesions.
The median follow up was 16 months (IQR 12.2–22.85). The cohort
characteristics are summarised in Table 1. Toxicity was consistent
Nodal oligometastatic colorectal cancer and SBRTwith published series and is available elsewhere, with no deaths
due to SBRT [20]. The median BED10 for the all sites was 79.2 Gy.
All lesions received the prescribed dose. Only 23% of patients had
not received prior systemic therapy prior to SBRT. KRAS mutation
status was available for 64 (39%) of patients.
The 1 and 2 year local control rate for the whole cohort was
83.8% (CI 76.4%91.9%) and 77.4% (CI 67.9%88.2%) respectively.
However, the 1 year local control rate varied significantly different
according to treated site; 58% for liver (36.7%92.7%), 90% for
lymph nodes (82.9%99%) and 92% for lung (80.3%100%).
In total, 86 patients with 95 lymph nodes metastases were trea-
ted. These were mapped to four anatomical locations: medi-
astinum, upper abdomen, para-aortic nodes and pelvic/inguinal
nodes [Fig. 1]. 53 out of 95 (56%) of nodes never progressed. Of
the remaining 42, only 2 progressed in-field and 12/42 (28%) pro-
gressed at multiple sites.
At 1 year and 2 years respectively, PFS for the whole cohort was
55% (CI 47%64.7%) and 37.6% (CI 29%48.8%) while OS was 93%
(88.6%98%) and 74% (CI 64.5%85.4%). Median PFS for the whole
cohort was 13.9 months, with median OS not reached. VM (liver,
lung & bone) had a worse median PFS (9 months vs 19 months)
and worse median OS (32 months vs not reached) than nodal
metastatic sites, reflected in a statistically significant difference
by Cox regression for PFS [HR 0.6, 95% 0.38–0.94, p = 0.032] and
OS [HR 0.28, 95% 0.18–0.7, p = 0.0062] [Fig. 2]. On univariate anal-
ysis there was no significant in PFS difference for ECOG PS, primary
site or synchronous/metachronous disease at presentation
(Table 2). Patients in receipt of chemotherapy (adjuvant or meta-
static) prior to SBRT had an increased hazard for progression [HR
1.93, C.I 1.08–3.45; p = 0.027]. On univariate analysis for OS, ECOG
PS 1 or 2 were associated with an increased risk of death, relative
to PS 0, but only the former was statistically significant with an
overall low number (5) of PS 2 patients [Table 2]. Patients who
had previously received systemic chemotherapy prior to SBRT
had an increased hazard for progression [HR 1.93, CI 1.08–3.45;
p = 0.027] and increased hazard for death, with a trend towards
statistical significance.
Significant factors on univariate testing were included in a mul-
tivariate analysis for PFS and OS [Table 2], where VM remained sig-
nificantly associated with poor outcomes. Inclusion of local control
in a OS multivariate cox model showed that poor local control and
an ECOG PS 1/2 were significantly associated with worse overall
survival (Supplementary Table 2). NM site was associated with
an improved OS outcome [HR 0.37, CI 0.14–0.95, p = 0.038].Fig. 1. Body diagram showing the anatomical sites of metastases with an associated cou
locoregional progression [LRP]).
282To understand if the improved outcomes of NM was due to the
large proportion of pelvic LN (50%), these were compared to dis-
tant, extra-pelvic NM sites and VM. On Cox regression analysis, rel-
ative to extra-pelvic LN, VM had an inferior PFS [HR 2.24, C.I 1.23–
4.17; p = 0.008] and inferior OS [13.9, C.I 1.85–105.6; p = 0.01] but
pelvic LN did not have significantly worse PFS [HR 1.86, C.I 0.94–
3.68; p = 0.074] or OS [HR 8.15, C.I 0.97–67.85; p = 0.052] [Fig. 3].
The effect of KRAS mutation status was explored in the sub-
group of patients for whom mutation testing of the primary
tumour was available (N = 64), 30% of which were KRAS mutant.
Other activating mutations, such as BRAF, were less common as
expected [22], and not detected in sufficient numbers for analysis.
There was no significant difference in the distribution of oligome-
tastatic sites (liver, node, lung, bone) by KRAS mutation (Fisher’s
exact test, p = 0.346). There was no difference in local control rates
between KRAS wild type and mutant cases (log rank p = 0.63)
[Fig. 3A]. KRAS wild type was associated with improved PFS [HR
0.42, 95% CI 0.2–0.87; p = 0.02] and OS [HR 0.2, 95% CI 0.05–
0.76; p = 0.02] [Supplementary Fig. 1]. The median PFS for wild
type was 13 months versus 7 for mutant patients. On multivariate
Cox regression analysis, nodal metastases and KRAS wild type
remained significant prognostic factors [Nodal HR 0.09, 95% CI
0.02–0.4, p = 0.002; KRAS wild type HR 0.1, 95% 0.01–0.5,
p = 0.007].
Discussion
In this prospectively collected, multicentre cohort study we
showed patients having SBRT for nodal oligometastases enjoy bet-
ter survival outcomes, relative to those treated for visceral metas-
tases. The cohort was accrued over a short period of time (3 years)
and had a LC at 1 and 2 years of 83.8% and 77.4%, respectively. LC in
liver metastases appeared to be worse compared to other sites
within the cohort and consistent with a systematic review of SBRT
in CRC [23], which estimated wide variation local control rates for
liver metastases of between 50%-100% at 1-year and 32%-91% at
2 years. Previous data had suggested that CRC patients with oligo-
metastatic disease to liver have worse outcomes compared to other
disease types treated with SBRT [13,24]. Radiosensitivity among
liver metastases from CRC is heterogeneous compared to other
sites [25] and this may account for the varying local controls rates
[23].
A recent large single-centre CRC demonstrated 1-year local con-
trol of 95% and 3-year rate of >70% for the whole cohort [11].nt grid indicating the outcome (distant progression [DP], in field progression [IFP],
Table 2
Univariate analysis for local control, progression free survival and overall survival.
LC PFS OS
Variable HR (CI) p value HR (CI) p value HR (CI) p value
ECOG PS
0 Reference
1 1.11 (0.43–2.86) 0.831 1.02 (0.63–1.65) 0.932 2.75 (1.13–6.68) 0.025*
2 2.28 (0.29–17.75) 0.43 0.51 (0.07–3.71) 0.506 4.85 (0.6–39.14) 0.138
Primary site
Rectum (ref Colon) 0.88 (0.37–2.12) 0.779 1.0 (0.64–1.55) 0.984 0.7 (0.31–1.57) 0.382
Prior chemotherapy (ref no chemotherapy) 1.71 (0.57–5.15) 0.337 1.93 (1.08–3.45) 0.027* 3.18 (0.94–10.72) 0.063
Synchronous presentation (ref metachronous) 0.88 (0.26–3.02) 0.842 1.61 (0.96–2.71) 0.070 1.32 (0.49–3.55) 0.579
Lymph node site (ref visceral site) 0.6 (0.25–1.46) 0.262 0.61 (0.39–0.96) 0.032* 0.29 (0.12–0.7) 0.006*
*Denotes statistically significant at the 0.05 level.
Fig. 2. Kaplan Meier plots with associated risk tables of progression free survival (A) and overall survival (B) outcomes for visceral (red) and nodal (blue) metastases.
S.M. O’Cathail et al. Radiotherapy and Oncology 151 (2020) 280–286Although there was no difference in LC between lung vs non-lung
metastases, they did not present the LC rates by site and had low
numbers of nodal sites (12.4%). Factors which negatively influ-
enced OS in multivariate analysis were non-lung sites [HR 1.97
(1.30–2.99), p = 0.02], CTV > 30 mm [HR 1.73 (1.18–2.55),
p = 0.03], systemic therapy before SBRT [HR 1.61 (1.01–2.57),
p = 0.023] and poor local control [HR 1.59 (1.04–2.43), p = 0.007].
Similar findings had been reported in a multi – tumour cohort283where prior systemic therapy resulted in worse LC [13]. A consis-
tent interpretation is that achieving good local control of treated
sites can lead to improved survival outcomes. Although local con-
trol, strictly speaking, is an outcome variable as opposed to pre-
treatment variable, and thus has no use in selecting patients for
SBRT, such analyses are common in SBRT cohorts. It should be
noted however that assessment of local control could vary
between reporting radiologists in a multi-institutional study,
Fig. 3. Kaplan Meier plots with associated risk tables of progression free survival (A) and overall survival (B) outcomes for pelvic NM, distant NM (outside the pelvis) and
visceral metastases.
Nodal oligometastatic colorectal cancer and SBRTimaging modalities and anatomical sites, particularly liver lesions.
Even though all participating centres were high volume, experi-
enced, accredited SBRT institutions this is a potential weakness
in our LC estimates.
The majority (56%) of nodal metastases never progressed in
field during follow up. Of the 42 that did progress, 12 patients
had LRP only and 28% had LRP and multi-site progression while
38% had distant disease. The pattern of relapse post SBRT justifies
considering local tumoricidal treatments only to isolated nodal dis-
ease. Introduction of CTV around NM may decrease LRP but would
increase toxicity. The excellent local control achieved with SBRT in
nodal disease translated into an improved time to progression (19
vs 9 months) and sustained into an OS benefit. Conversely, worse
local control as seen in the liver metastases, was associated with
worse OS in the multivariate analysis [HR 3.3 (95% CI 1.35 –
8.78), p = 0.016]. Given that 50% of visceral metastases had
progressed by 9 months suggests that in such patients SBRT and284systemic therapy could be better therapeutic approach, analogous
to liver resections.
KRAS mutation has recently been shown to be a prognostic
biomarker of worse survival outcomes in metastatic colorectal
cancer in a large meta-analysis of first line randomised
chemotherapy trials [26], an analogous situation to those referred
for SBRT. Kinj et al found that KRAS mutation was associated with
inferior metastasis free survival, but not OS, following SBRT in
lung metastases [14]. In a randomised phase II trial of proton
therapy for liver metastases KRAS mutants and TP53 mutants
had worse local control than wild type patients [24]. A recent
comprehensive study of tumour mutation status in a multisite
cohort [27] demonstrated similar findings. Interestingly, although
only 10% of their cohort, NM had 100% LC at 2 years. We suggest
that KRAS mutation is a relevant prognostic factor in oligometa-
static CRC and be incorporated as a stratifying factor into future
SBRT studies.
S.M. O’Cathail et al. Radiotherapy and Oncology 151 (2020) 280–286Our study has limitations. Our median follow up is shorter than
some published datasets [11,28,29], but not all [30], in part due to
data collection permissions. However, the significant majority of
relapse events after surgery occur in the first 2–3 years [2]. Our
cohort had already accrued 6 months DFS prior to entry in the SBRT
program, in addition to the median follow up which was calculated
from date of SBRT. Our cohort represents a very clear subset of the
recent ESTRO/EORTC OMD classifier [31] – metastatic oligorecur-
rence – which represents 83% [Table 1] and should be interpreted
as such. We did not have histological and molecular mutation con-
firmation of every treated site and thus inferred KRAS status. KRAS
status of the primary tumour shows high concordance with muta-
tion status in tissue sampled from metastases [32–34] however.
Given the small sample numbers of known KRAS patients, the anal-
ysis could be subject overfitting in MVA and is considered hypoth-
esis generating.
Although a variety of radiotherapy doses were used, leading to
range of BED, each site was treated consistently with the same
dose. The schedules used are equivalent to those mandated in
the SABR-COMET trial [7]. BEDmax has previously been attributed
to improved LC in liver metastases [12,13]. An analysis of dose
effect on outcomes is not possible as it is confounded by treated
site. Here, NM had the best LC despite the lowest prescription dose
(BED10 60–93.3 Gy) suggesting more fundamental biological differ-
ences in radiation response between sites.
One potential working hypothesis for the observed differences
are different routes of spread, with visceral metastases spreading
haematologically and nodal metastases through the lymphatic sys-
tem. The ability of the immune system to influence a cancer’s clin-
ical course – ‘‘cancer immunoediting” - is marked by three distinct
phases: elimination, equilibrium, and escape [35]. The clinical exis-
tence of oligometastases suggests that these tumours have escaped
cancer immunoediting. LN are historically viewed as production
sites for antigen-specific (adaptive) effector cells but they also con-
tain a spatially co-ordinated diverse multicellular network of lym-
phoid cells (innate) that can rapidly generate a cytokine response
[36]. Radiotherapy engages both the adaptive and innate immune
system to convert the irradiated tumour into an ‘in-situ vaccine’
that elicits a tumour specific T-cell response [37]. In doing so,
radiotherapy can assist recalibration of the immunoediting pro-
cess, switching escape back to elimination and equilibrium. Once
an oligometastatic site is treated, the ‘vaccinated’ individual may
have the immune memory capacity to prevent (elimination) or
defer (equilibrium) the development of synchronous disease sites.
In support of this theory, a recent study by Pitroda et al, of inte-
grated molecular analysis of CRC metastases, an immune enriched
subtype developed limited numbers of clinically evident syn-
chronous metastases and was associated with improved survival
outcomes [38]. These data would be consistent with the immu-
noediting hypothesis. Furthermore, they demonstrated that
increased KRAS signalling was associated with worse survival out-
comes, consistent with our data.
Treatment options for metastatic CRC are slow to progress com-
pared to other common cancers, with cytotoxic chemotherapy still
the mainstay of treatment. SBRT is an excellent tool that offers a
radical, potentially curative, option to patients with limited disease
spread. However, optimum selection of patients and sequencing of
therapies to maximise benefit has yet to be clarified. The current
study represents an important step forward in highlighting the
need for biological selection of patients for SBRT, in addition to
known clinical factors. A better understanding of the local and cir-
culating immune response generated by SBRT is needed to fully
explain the varying outcomes seen in this and other studies of oli-
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